What helps you in your fight?

TYSABRI can help in 3 important ways

In a 2-year study of 627 people treated with TYSABRI versus 315 people taking placebo, TYSABRI was significantly more effective in slowing the progression of physical disability evaluated over a period of 12 weeks, reducing the formation of new active brain lesions, and reducing the number of relapses. Want to learn more about TYSABRI?

of people treated with TYSABRI had no
progression of physical disability
* (compared to 71% taking placebo)

  • 17% of people treated with TYSABRI had worsening physical disability, compared with 29% of people taking placebo

of people treated with TYSABRI remained relapse free* (compared to 41% taking placebo)

  • 67% of people taking TYSABRI were relapse free

of people treated with TYSABRI had no new Gd-enhanced lesions that showed disease activity on an MRI* (compared to 72% taking placebo)

*In a 2-year study of 627 people treated with TYSABRI versus 315 taking placebo.